35551-31-6

Basic information

• Product Name: 2(1H)-Pyrimidinone, 4-(methylthio)- (9CI)
• Synonyms: 2(1H)-Pyrimidinone, 4-(methylthio)- (9CI);4-(methylthio)-2(1H)-pyrimidinone
• CAS NO: 35551-31-6
• Molecular Formula: C₅H₆N₂OS
• Molecular Weight: 142.17894
• Product Categories: PYRIMIDINE
• Mol File: 35551-31-6.mol

Chemical Properties

• Boiling Point: °Cat760mmHg
• Flash Point: °C
• Appearance: /
• Density: 1.35g/cm³
• Refractive Index: 1.638
• CAS DataBase Reference: 2(1H)-Pyrimidinone, 4-(methylthio)- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 2(1H)-Pyrimidinone, 4-(methylthio)- (9CI)(35551-31-6)
• EPA Substance Registry System: 2(1H)-Pyrimidinone, 4-(methylthio)- (9CI)(35551-31-6)

Safety Data

• Hazardous Substances Data: 35551-31-6(Hazardous Substances Data)

Usage

Molecular Structure

2(1H)-Pyrimidinone, 4-(methylthio)(9CI) consists of a pyrimidinone ring with a methylthio group attached to the fourth carbon atom.

Molecular Weight

129.17 g/mol

Appearance

Pale yellow solid

Solubility

Slightly soluble in water, soluble in common organic solvents such as ethanol, methanol, and acetone.

Melting Point

198-200°C

Boiling Point

Not available as it is a solid

Polarity

Polar due to the presence of the pyrimidinone ring and the methylthio group.

Functional Groups

Pyrimidinone ring, methylthio group.

Uses

In the synthesis of various pharmaceuticals and agrochemicals, as a building block in organic synthesis, and as a starting material for the synthesis of other compounds.

Natural Occurrence

Found in some natural products.

InChI:InChI=1/C5H6N2OS/c1-9-4-2-3-6-5(8)7-4/h2-3H,1H3,(H,6,7,8)

Upstream product

• 74-88-4 methyl iodide 
• 591-28-6 4-thiouracil 
• 684-93-5 1-methyl-1-nitrosourea 

Downstream Products

• 127970-31-4 4-N-para-toloylcytosine 
• 127970-34-7 N⁴-(4'-chlorophenyl)cytosine 
• 29840-44-6 4-(phenylamino)pyrimidin-2(1H)-one 
• 127970-33-6 N⁴-(3'-chlorophenyl)cytosine 
• 127970-32-5 N⁴-(2'-chlorophenyl)cytosine 
• 127970-30-3 4-m-Tolylamino-1H-pyrimidin-2-one 
• 127970-29-0 4-o-toluidino-1H-pyrimidin-2-one 
• 20555-88-8 N⁴-hydroxycytosine 
• 1243253-28-2 1-(4-(2-hydroxy-2-methylpropoxy)-3-methoxyphenyl)-4-(methylthio)pyrimidin-2(1H)-one 
• 1359871-45-6 N-{[4-(methylsulfanyl)-2-oxopyrimidin-1(2H)-yl]acetyl}-L-phenylglycine methyl ester 
• 6220-47-9 4-(Methylamino)-2(1H)-pyrimidinone 
• 66-22-8 uracil 
• 71-30-7 Cytosine 
• 591-28-6 4-thiouracil 

Relevant articles and documents

Liquid crystals resulting from combined ionic and hydrogen bonding interactions of nucleobase derivatives

Salts derived from the interaction of guanine or cytosine acid derivatives with hexadecylamine exhibited smectic liquid crystalline character. This behavior was attributed to a two-level organization process, i.e., to the segregation of lipophilic from hydrophilic moieties due to the formation of the n-alkylammonium salts and to the self-dimerization of these salts through molecular recognition. Furthermore, mixing of the complementary salts in 1:1 molar ratio led, at elevated temperatures, to the formation of their heterodimer which also exhibited a smectic liquid crystalline phase.

A one-pot, water compatible synthesis of pyrimidine nucleobases under plausible prebiotic conditions

Herein, we report a new prebiotically plausible pathway towards a pyrimidine nucleobase in continuous manner. The route involves simultaneous methylation and carbamoylation of cyanoacetylene-derived α,β-unsaturated thioamide with N-methyl-N-nitrosourea (MNU) in aqueous media. This provides S-methylpyrimidinone in one-pot, which can be converted into a variety of 4-substituted pyrimidine nucleobases including cytosine and uracil.

AZA PYRIDONE ANALOGS USEFUL AS MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS

MCHR1 antagonists are provided having the following Formula (I): A 1 and A 2 are independently C or N, E is C or N, Q 1 , Q 2 , and Q 3 are independently C or N provided that at least one of Q 1 , Q 2 , and Q 3 is N but not more than one of Q 1 , Q 2 , and Q 3 is N, D 1 is a bond, -CR 8 R 9 X-, -XCR 8 R 9 -, -CHR 8 CHR 9 -, -CR 10 =CR 10' -, -C-C-, or 1,2-cyclopropyl; X is O, S or NR 11, R 1 , R 2 , and R 3 are ,independently selected from the group consisting of hydrogen, halogen, lower alkyl, lower cycloalkyl, -CF 3 , -OCF 3 , -OR 12 and -SR 12, G is O, S or -NR 15, D 2 is lower alkyl, lower cycloalkyl, lower alkylcycloalkyl, lower cycloalkylalkyl, lower cycloalkoxyalkyl or lower alkylcycloalkoxy or when G is NR 15 , G and D 2 together may optionally form an azetidine, pyrrolidine or piperidine ring; Z 1 and Z 2 are independently hydrogen, lower alkyl, lower cycloalkyl, lower alkoxy, lower cycloalkoxy, halo, -CF 3 , -OCONR 14 R 14' , -CN, -CONR 14 R 14' , -SOR 12 , -SO 2 R 12 , -NR 14 COR 14' , -NR 14 CO 2 R 14' , -CO 2 R 12 , NR 14 SO 2 R 12 or COR 12 ; R 5 , R 6 , and R 7 are independently selected from the group consisting of hydrogen lower alkyl, lower cycloalkyl, -CF 3 , -SR 12 , lower alkoxy, lower cycloalkoxy, -CN, -CONR 14 R 14' , SOR 12 , SO 2 R 12 , NR 14 COR 14' , NR 14 CO 2 R 12 , CO 2 R 12 , NR 14 SO 2 R 12 and -COR 12 ; R 8 , R 9 , R 10 , R 10' , R 11 are independently hydrogen or lower alkyl; R 12 is lower alkyl or lower cycloalkyl; R 14 and R 14' are independently H, lower alkyl, lower cycloalkyl or R 14 and R 14' together with the N to which they are attached form a ring having 4 to 7 atoms; and R 15 is independently selected from the group consisting of hydrogen and lower alkyl. Such compounds are useful for the treatment of MCHR1 mediated diseases, such as obesity, diabetes, IBD, depression, and anxiety

Synthesis of modified pyrimidine bases and positive impact of chemically reactive substituents on their in vitro antiproliferative activity

The antiproliferative activity screening on human tumor cell lines of a series of modified uracil and cytosine bases as well as some corresponding acyclonucleosides, and comparison of structure-activity relationship revealed the importance of chemical rea